Sanofi has put off a biosimilar threat to Lantus till the end of 2016. In a patent settlement announced on Monday, the French drugmaker and U.S.-based Eli Lilly & Co. agreed to a royalty deal covering ...

After years of manufacturing woes torpedoed their chances to challenge Sanofi's blockbuster insulin injection Lantus, Mylan and Biocon recently received the FDA's go-ahead to launch their knockoff.

California will soon become the first state to offer its own affordable insulin, with Gov. Gavin Newsom announcing that CalRx ...

Californians will be able to buy five packs of insulin pens for a maximum of $55 per pack, or $11 per pen, starting Jan. 1, ...

California will begin offering its own brand of low-cost insulin in 2026, becoming the first state to contract for and sell ...

As we previously reported, Sanofi has appealed the decisions in IPR2017-01526 and IPR2017-01527 finding the challenged claims of U.S. Patent Nos. 7,476,652 and 7,713,930 invalid to the U.S. Court of ...

On July 5, Mylan announced another voluntary recall of a batch of Insulin Glargine (insulin glargine-yfgn) Injection, 100 units/mL (U-100), 3 mL prefilled pens “due to the potential for the label to ...

Basaglar (insulin glargine) and Lantus (insulin glargine) are brand-name prescription medications. They’re approved by the Food and Drug Administration (FDA) to: improve blood sugar levels in adults ...

The FDA approved a 900-unit insulin glargine pen, the highest capacity long-acting insulin pen on the market in the U.S., Sanofi announced in a press release. The new insulin glargine (Toujeo) Max ...

Mylan Pharmaceuticals has recalled some insulin-glargine injection pens because they may be missing labels. According to an announcement with the U.S. Food and Drug Administration, the lack of a label ...